- Home
- BIIB vs GDDY Comparison
BIIB vs GDDY Comparison
Compare BIIB & GDDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- GDDY
- Stock Information
- Founded
- BIIB 1978
- GDDY 1997
- Country
- BIIB United States
- GDDY United States
- Employees
- BIIB N/A
- GDDY N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- GDDY EDP Services
- Sector
- BIIB Health Care
- GDDY Technology
- Exchange
- BIIB Nasdaq
- GDDY Nasdaq
- Market Cap
- BIIB 25.1B
- GDDY 22.0B
- IPO Year
- BIIB 1991
- GDDY 2015
- Fundamental
- Price
- BIIB $160.92
- GDDY $208.14
- Analyst Decision
- BIIB Buy
- GDDY Buy
- Analyst Count
- BIIB 25
- GDDY 15
- Target Price
- BIIB $258.57
- GDDY $172.21
- AVG Volume (30 Days)
- BIIB 1.6M
- GDDY 1.4M
- Earning Date
- BIIB 10-30-2024
- GDDY 10-30-2024
- Dividend Yield
- BIIB N/A
- GDDY N/A
- EPS Growth
- BIIB 10.05
- GDDY 452.19
- EPS
- BIIB 11.06
- GDDY 12.74
- Revenue
- BIIB $9,607,500,000.00
- GDDY $4,480,900,000.00
- Revenue This Year
- BIIB N/A
- GDDY $9.28
- Revenue Next Year
- BIIB N/A
- GDDY $7.49
- P/E Ratio
- BIIB $14.55
- GDDY $16.33
- Revenue Growth
- BIIB N/A
- GDDY 6.85
- 52 Week Low
- BIIB $153.62
- GDDY $99.90
- 52 Week High
- BIIB $268.30
- GDDY $208.71
- Technical
- Relative Strength Index (RSI)
- BIIB 37.88
- GDDY 83.26
- Support Level
- BIIB $158.44
- GDDY $194.83
- Resistance Level
- BIIB $165.29
- GDDY $199.99
- Average True Range (ATR)
- BIIB 4.00
- GDDY 4.28
- MACD
- BIIB 1.10
- GDDY 0.68
- Stochastic Oscillator
- BIIB 32.82
- GDDY 97.88
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About GDDY GoDaddy Inc.
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.